Institute of Neuropathology, University Hospital Münster, Domagkstr. 19, Münster, Germany.
Glia. 2012 Feb;60(2):271-80. doi: 10.1002/glia.21261. Epub 2011 Nov 7.
Oligodendroglial damage and loss are typical characteristics of demyelinating diseases such as multiple sclerosis (MS) and the leukodystrophies. Axonal loss is the underlying cause of permanent neurological deficits in MS and it is thought to arise from a combination of immune-mediated axonal damage and the loss of trophic support to axons from myelin sheaths after demyelination. Prevention of oligodendroglial damage or death and demyelination are therefore attractive neuroprotective treatment strategies. However, a better understanding of mechanisms leading to oligodendroglial damage and demyelination is a prerequisite for the development of such treatment options. Here, we demonstrate that X-linked inhibitor of apoptosis (XIAP), the most potent member of the inhibitor of apoptosis proteins (IAP) family is expressed in oligodendrocytes in vivo and in vitro. Increased expression of XIAP is associated with protection against selected cell death pathways, whereas decreased expression increases oligodendroglial cell death in vitro. However, lack of XIAP does not modulate oligodendroglial cell death in toxic demyelination in vivo.
少突胶质细胞损伤和缺失是脱髓鞘疾病(如多发性硬化症(MS)和白质营养不良)的典型特征。轴突丢失是 MS 中永久性神经功能缺损的根本原因,据认为它是由免疫介导的轴突损伤和脱髓鞘后髓鞘对轴突的营养支持丧失共同引起的。因此,预防少突胶质细胞损伤或死亡和脱髓鞘是有吸引力的神经保护治疗策略。然而,更好地了解导致少突胶质细胞损伤和脱髓鞘的机制是开发此类治疗选择的前提。在这里,我们证明了凋亡抑制蛋白(IAP)家族中最有效的成员 X 连锁凋亡抑制剂(XIAP)在体内和体外均表达于少突胶质细胞中。XIAP 的表达增加与对选定的细胞死亡途径的保护有关,而表达减少则增加体外少突胶质细胞的死亡。然而,XIAP 的缺乏并不调节体内毒性脱髓鞘中的少突胶质细胞死亡。